{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:52:15Z","timestamp":1789519935536,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.atherosclerosis.2026.120670","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:18:50Z","timestamp":1770682730000},"page":"120670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The evolving therapeutic landscape of PCSK9 inhibition"],"prefix":"10.1016","volume":"414","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-7041","authenticated-orcid":false,"given":"Brett S.","family":"Mansfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakubu","family":"Bene-Alhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.120670_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib2","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global Burden of Disease Study 2021","volume":"403","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001209","article-title":"Heart disease and stroke statistics: a report of US and global data from the American heart Association","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"The Lancet Regional Health - Europe"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wi d e Cross-Section a l Obser v at i o n al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib7","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMc0707445","article-title":"A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib9","unstructured":"Kaufman TM, Warden BA, Minnier J, Miles JR, Duell PB, Purnell JQ, et al. Application of PCSK9 inhibitors in practice."},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib10","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-Term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib14","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib17","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib18","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/jamacardio.2024.3200","article-title":"Lesion-Level effects of LDL-C\u2013Lowering therapy in patients with acute myocardial infarction: a post hoc analysis of the PACMAN-AMI trial","volume":"9","author":"Biccir\u00e8","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib19","article-title":"Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial","volume":"41","author":"Huo","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12916-023-02797-8","article-title":"Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)","volume":"21","author":"Chai","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib21","first-page":"636","article-title":"Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4)","volume":"3","author":"Qi","year":"2023","journal-title":"JACC (J Am Coll Cardiol): Asia"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib22","first-page":"411","article-title":"A potential long-acting LDL-Cholesterol\u2013Lowering PCSK9 monoclonal antibody","volume":"1","author":"Cui","year":"2021","journal-title":"JACC (J Am Coll Cardiol): Asia"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40256-024-00654-4","article-title":"The efficacy of tafolecimab in Chinese patients with hypercholesterolemia: a systematic review and meta-analysis","volume":"24","author":"Fatima","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s40265-023-01952-y","article-title":"Tafolecimab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib25","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-Reduction variability and antidrug-antibody Formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120408","article-title":"Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial","volume":"407","author":"Shao","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib27","article-title":"Efficacy and safety of Ongericimab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia","volume":"vol. 13","author":"Wang","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119120","article-title":"Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"403","author":"Lin","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib29","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","article-title":"Recaticimab as Add-On therapy to statins for nonfamilial hypercholesterolemia","volume":"84","author":"Sun","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib30","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","article-title":"Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia","volume":"84","author":"Xu","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib31","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0735-1097(24)03697-0","article-title":"PCSK9 monoclonal antibody RECATICIMAB in adult heterozygous familial hypercholesterolemia (REMAIN-3): a multicenter, randomized, double-blind, placebo-controlled phase 3 study","volume":"83","author":"Jiyan","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13318-025-00944-5","article-title":"A phase I study to evaluate the relative bioavailability, pharmacodynamics, and safety of a single subcutaneous injection of recaticimab at three different sites in healthy Chinese subjects","volume":"50","author":"Wang","year":"2025","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib33","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-025-02199-5","article-title":"Recaticimab: first approval","volume":"85","author":"Lamb","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib34","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib35","first-page":"800","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol American Medical Association (AMA)"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S2213-8587(24)00313-9","article-title":"Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial","volume":"13","author":"Raal","year":"2025","journal-title":"The Lancet Diabetes & Endocrinology Elsevier BV"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119493","article-title":"Lerodalcibep and adjudicated cardiovascular events in a pre-defined pooled analysis of three large long term phase III studies","volume":"407","author":"Kallend","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib39","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N -Acetylgalactosamine-Conjugated siRNA localizes in hepatocytes and elicits robust RNAi-Mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib40","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2025.04.049","article-title":"Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD","volume":"86","author":"Taub","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib43","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib45","first-page":"144","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation","volume":"148","author":"Johns","year":"2023","journal-title":"American Heart Association"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib46","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial","author":"Ballantyne","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib48","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib49","first-page":"844","article-title":"ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk","volume":"19","author":"Sehayek","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib53","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An oral PCSK9 inhibitor for treatment of Hypercholesterolemia: the PURSUIT randomized trial","volume":"85","author":"Koren","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib54","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.jacc.2025.03.518","article-title":"Oral PCSK9 inhibitors: can novel therapies overcome barriers to effective LDL-cholesterol management?","volume":"85","author":"Ballantyne","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","article-title":"PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial","volume":"12","author":"Koren","year":"2024","journal-title":"The Lancet Diabetes & Endocrinology Elsevier"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib56","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","article-title":"VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol","volume":"33","author":"Hooper","year":"2024","journal-title":"Expert Opinion on Investigational Drugs Taylor & Francis"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib59","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-023-37465-1","article-title":"GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy","volume":"14","author":"Kasiewicz","year":"2023","journal-title":"Nat Commun Nature Publishing Group"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib62","series-title":"Human gene therapy products incorporating human genome editing [Internet]","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13863","article-title":"Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: the LIPID\u2010REAL registry","volume":"52","author":"Cordero","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib64","article-title":"Impact of proprotein convertase subtilisin\/Kexin type 9 inhibitors on Lipoprotein(a)","volume":"4","author":"Rivera","year":"2025","journal-title":"JACC (J Am Coll Cardiol): Advances"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib65","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib66","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","author":"Bohula","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib67","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non\u2013high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12872-024-04057-w","article-title":"Early administration of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"24","author":"Hosseini","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131775","article-title":"The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: a systematic review and meta-analysis","volume":"399","author":"Yifan","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib70","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib71","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","article-title":"Strike early\u2013strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry","volume":"31","author":"Gargiulo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib72","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ehjcvp\/pvaf004","article-title":"Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction","volume":"11","author":"Patti","year":"2025","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib73","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib74","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib76","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","article-title":"PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection","volume":"81","author":"Navarese","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib77","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2024.11.009","article-title":"A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor","volume":"188","author":"Mei","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib78","article-title":"PCSK9 promotes the malignancy of triple\u2010negative breast cancer cells by reducing cholesterol levels at the plasma membrane to activate EGFR and HER3","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib79","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib80","article-title":"Genetic assessment of potential long-term On-Target side effects of PCSK9 (Proprotein convertase Subtilisin\/Kexin type 9) inhibitors","volume":"12","author":"Nelson","year":"2019","journal-title":"Circ: Genomic and Precision Medicine"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib81","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib82","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses","volume":"n1537","author":"Cai","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib83","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/S0140-6736(24)02089-0","article-title":"Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)","volume":"404","author":"Strandberg","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib84","unstructured":"Holmes MV. PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations."},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib85","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12891-024-07674-w","article-title":"PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis","volume":"25","author":"Chen","year":"2024","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib86","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/eurjpc\/zwad402","article-title":"Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations","volume":"31","author":"Ardissino","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib87","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.3390\/jcm13144160","article-title":"The hurdle of access to emerging therapies and potential solutions in the management of Dyslipidemias","volume":"13","author":"Mansfield","year":"2024","journal-title":"JCM"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2022.02.008","article-title":"Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: an analysis of international sales data","volume":"248","author":"Blais","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib89","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020126","article-title":"Treatment inertia in patients with familial hypercholesterolemia","volume":"10","author":"Langer","year":"2021","journal-title":"JAHA"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib90","article-title":"Trends in patient access to and utilization of prescribed PCSK9 inhibitors in a large US claims database from 2015 to","volume":"17","author":"MacDougall","year":"2021","journal-title":"Circ: Cardiovascular Quality and Outcomes"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib91","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40256-020-00411-3","article-title":"PCSK9 inhibitors in a German single-center clinical practice: Real-World treatment of patients at high cardiovascular risk over 68 weeks","volume":"21","author":"Hollstein","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib92","doi-asserted-by":"crossref","DOI":"10.1177\/17539447231213288","article-title":"Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study","volume":"18","author":"Sudano","year":"2024","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"key":"10.1016\/j.atherosclerosis.2026.120670_bib93","article-title":"Inadequate response to PCSK9 inhibitors","volume":"30","author":"Bimal","year":"2025","journal-title":"JACC Case Rep"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2026.120670_bib94","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:59:37Z","timestamp":1773856777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":87,"alternative-id":["S0021915026000365"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120670","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving therapeutic landscape of PCSK9 inhibition","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120670"}}